Immune evasion mechanism and its clinical application value in Hodgkin′s lymphoma
10.3760/cma.j.cn112152-20200623-00591
- VernacularTitle:霍奇金淋巴瘤免疫逃逸机制及其临床应用价值
- Author:
Yunxia TAO
1
;
Yuankai SHI
Author Information
1. 国家癌症中心 国家肿瘤临床医学研究中心 中国医学科学院北京协和医学院肿瘤医院内科 抗肿瘤分子靶向药物临床研究北京市重点实验室 100021
- Keywords:
Hodgkin′s lymphoma;
Immune evasion;
Tumor microenvironment;
Prognostic marker;
New drug
- From:
Chinese Journal of Oncology
2021;43(9):917-923
- CountryChina
- Language:Chinese
-
Abstract:
Hodgkin′s lymphoma (HL) is a unique malignancy in which rare malignant Hodgkin and Reed-Sternberg (HRS) cells are scattered in the inflammatory cell rich microenvironment. This extensive but ineffective inflammatory cell infiltrate indicates that HRS cells have developed mechanisms to evade immune surveillance. The immune escape mechanisms of HL provide prognostic biomarkers and opportunities to develop new drugs. The immune evasion mechanisms in Hodgkin lymphoma include a reduction of human leukocyte antigen (HLA) to affect first signal which is essential for T cell activation; an upregulation of negative co-stimulatory molecules to inhibit T cell activation; resistance to apoptosis or killing by expressing some molecules on HRS cells membrane; an immunosuppressive network formed by HRS cells regulating the microenvironment immune cells. Immune escape mechanisms of HRS cells provide new targets for the development of new drug and the new drug development strategies include drugs on HRS cells and drugs on microenvironment.
